1.
Seal MD, Speers CH, O’Reilly S, Gelmon KA, Ellard SL, Chia SK (2012) Outcomes of women with early-stage breast cancer receiving adjuvant trastuzumab. Curr Oncol 19:1–5

2.
Bria E, Cuppone F, Fornier M, Nisticò C, Carlini P, Milella M et al (2008) Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 109:231–239

3.
Kaplan MA, Ertugrul H, Firat U, Kucukoner M, İnal A, Urakci Z et al (2015) Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab. Breast Cancer 22:1–7

4.
Lai R, Dang CT, Malkin MG, Abrey LE (2004) The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101:810–816

5.
Murrell DH, Hamilton AM, Mallett CL, van Gorkum R, Chambers AF, Foster PJ (2015) Understanding heterogeneity and permeability of brain metastases in murine models of HER2-positive breast cancer through magnetic resonance imaging: implications for detection and therapy. Transl Oncol 8:176–184

6.
Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15:219–225

7.
Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583–592

8.
Kyle AH, Baker JHE, Gandolfo M-J, Reinsberg SA, Minchinton AI (2014) Tissue penetration and activity of camptothecins in solid tumor xenografts. Mol Cancer Ther.  https://doi.org/10.1158/1535-7163.MCT-14-0475

9.
Kyle AH, Huxham LA, Yeoman DM, Minchinton AI (2007) Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res 13:2804–2810

10.
Huxham LA, Kyle AH, Baker JHE, Nykilchuk LK, Minchinton AI (2004) Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 64:6537–6541

11.
Kyle AH, Huxham LA, Chiam ASJ, Sim DH, Minchinton AI (2004) Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture. Cancer Res 64:6304–6309

12.
Kyle AH, Minchinton AI (1999) Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother Pharmacol 43:213–220

13.
Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7:653–664

14.
Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK (2011) Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2:281–298

15.
Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W et al (1992) Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 52:5144–5153

16.
Baker JHE, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI (2008) Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 14:2171–2179

17.
Lee CM, Tannock IF (2010) The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer 10:255

18.
Trotter M, Chaplin D, Olive P (1989) Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br J Cancer 59:706–709

19.
Baker JHE, McPhee KC, Moosvi F, Saatchi K, Hafeli UO, Minchinton AI et al (2015) Multi-modal magnetic resonance imaging and histology of vascular function in xenografts using macromolecular contrast agent hyperbranched polyglycerol (HPG-GdF). Contrast Media Mol. Imaging 11:77–88

20.
Kainthan RK, Muliawan EB, Hatzikiriakos SG, Brooks DE (2006) Synthesis, characterization, and viscoelastic properties of high molecular weight hyperbranched polyglycerols. Macromol Am Chem Soc 39:7708–7717

21.
Saatchi K, Soema P, Gelder N, Misri R, McPhee K, Baker JHE et al (2012) Hyperbranched polyglycerols as trimodal imaging agents: design, biocompatibility, and tumor uptake. Bioconjug Chem 23:372–381

22.
Bains LJ, Baker JHE, Kyle AH, Minchinton AI, Reinsberg SA (2009) Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 74:957–965

23.
Collins TJ (2007) ImageJ for microscopy. Biotechniques 43:S25–S30

24.
Adkins CE, Mohammad AS, Terrell-Hall TB, Dolan EL, Shah N, Sechrest E et al (2016) Characterization of passive permeability at the blood–tumor barrier in five preclinical models of brain metastases of breast cancer. Clin Exp Metastasis 33:373–383

25.
Mittapalli RK, Adkins CE, Bohn KA, Mohammad AS, Lockman JA, Lockman PR (2017) Quantitative fluorescence microscopy measures vascular pore size in primary and metastatic brain tumors. Cancer Res 77:238–246

26.
Nounou MI, Adkins CE, Rubinchik E, Terrell-Hall TB, Afroz M, Vitalis T, Gabathuler R, Tian MM, Lockman PR (2016) Anti-cancer antibody trastuzumab-melanotransferrin conjugate (BT2III) for the treatment of metastatic HER2 + breast cancer tumors in the brain: an in vivo study. Pharm Res 33:2930–2942

27.
Terrell-Hall TB, Nounou MI, El-Amrawy F, Griffith JIG, Lockman PR (2017) Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer. Oncotarget 8(48):83734–83744

28.
Lewis Phillips GD, Nishimura MC, Arca Lacap J, Kharbanda S, Mai E, Tien J, Malesky K, Williams SP, Marik J, Phillips HS (2017) Trasutuzmab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis. Breast Cancer Res Treat 164:581–591

29.
Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schroder CP, Lub-de Hooge MN, de Vries EG (2010) Biodistribution of 89Zr-trastuzumab and PEG imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87(5):586–592

30.
Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, Tani H, Miakita Y, Kanayama Y, Wada Y, Kodaira M, Yunokawa M, Yamamoto H, Shimizu C, Takahashi K, Watanabe Y, Fijiwara Y, Tamura K (2015) EJNMMI Res 5:8

31.
Thurber GM, Wittrup KD (2012) A mechanistic compartmental model for total antibody uptake in tumors. J Theor Biol 314:57–68

32.
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071–1121

33.
Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328–335

34.
Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha Van Scheltinga AGT, Gietema JA, Garbacik ET et al (2013) Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 73:3347–3355

35.
Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S et al (2012) Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 11:752–762

36.
Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X et al (2013) AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31:1719–1725

37.
Sledge GW (2015) Anti-vascular endothelial growth factor therapy in breast cancer: game over? J Clin Oncol 33:133–135

38.
Jain RK (2013) Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 31:2205–2218

39.
Chauhan VP, Stylianopoulos T, Martin JD, Popović Z, Chen O, Kamoun WS et al (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 383:1–6

40.
Olson E (2013) When standard therapy fails in breast cancer: current and future options for HER2-positive disease. J Clinic Trials 03:1000129

41.
Spector NL, Blackwell KL (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27:5838–5847

42.
Van der Veldt AAM, Lammertsma AA, Smit EF (2012) Scheduling of anticancer drugs: timing may be everything. Cell Cycle 11:4339–4343

43.
Lam KO, Lee VHF, Liu RKY, Leung TW, Kwong DLW (2013) Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. Oncol Lett 5:637–640
